Browsing Category
Healthcare Industry News
2470 posts
Inside Talkspace’s plan to merge AI, social connection, and therapy through the Wisdo Health acquisition
Find out how Talkspace’s acquisition of Wisdo Health merges AI, peer support, and therapy to reinvent digital mental health care.
How NanoPhoria’s record €83.5m raise could transform heart failure treatment—and put Italian biotech on the global map
NanoPhoria Bioscience raises €83.5M to advance its novel heart-failure therapy and expand its nano delivery platform. Find out how it’s changing biotech today.
Why 4DMedical (ASX: 4DX) stock is gaining momentum after A$22.6m option exercise and cash runway boost
4DMedical (ASX: 4DX) raises A$22.6m via option exercise, boosting its cash balance to A$45.5m. Investors eye CT:VQ rollout and RSNA 2025 milestones.
Leo Cancer Care explores TibaRay linacs to power development of Grace photon therapy platform
Leo Cancer Care is evaluating TibaRay linacs for its Grace photon therapy platform, signaling a new era in upright and FLASH radiotherapy innovation.
AmeriWater expands sterile processing ST108 portfolio with remote monitoring analytics
AmeriWater launches remote monitoring for its ST108 sterile processing water systems, helping hospitals simplify compliance and safeguard patient safety.
RWJBarnabas Health and Rendina open new ambulatory care hub in Old Bridge to expand patient access
RWJBarnabas Health and Rendina open a 71,000-sq-ft ambulatory care hub in Old Bridge, reshaping patient access with urgent and specialty services.
Why OSE Immunotherapeutics stock is moving after Marc Le Bozec replaces Nicolas Poirier as CEO
OSE Immunotherapeutics ousts CEO Nicolas Poirier, names Marc Le Bozec interim chief and launches a strategic review. See what it means for investors.
Is Alphabet finally ready to cut ties with Verily after a decade of costly health care moonshots?
Bloomberg reports that Alphabet is preparing to sell or spin off Verily, marking a major shift in Big Tech’s health sciences strategy.
From IPO to $250M shelf: Can BioAge Labs keep investor faith in the race for anti-aging drugs?
BioAge Labs (NASDAQ: BIOA) files $250M mixed securities shelf to fuel its aging drug pipeline. See what it means for investors today.
Why did XOMA give shareholders two more weeks on the LAVA Therapeutics deal – and what happens next?
XOMA (NASDAQ: XOMA) extends its tender offer for LAVA Therapeutics (NASDAQ: LVTX) to Oct 17. Explore shareholder impact, CVR value, and deal prospects.